Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)

被引:473
|
作者
Fernandez, FG
Drebin, JA
Linehan, DC
Dehdashti, F
Siegel, BA
Strasberg, SM
机构
[1] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, Sect Hepatobiliary Pancreat Surg,Dept Surg,Div Nu, St Louis, MO 63110 USA
[2] Washington Univ, Med Ctr, Siteman Canc Ctr, St Louis, MO 63110 USA
关键词
D O I
10.1097/01.sla.0000138076.72547.b1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To report the first 5-year overall survival results in patients with colorectal carcinoma metastatic to the liver who have undergone hepatic resection after staging with [F-18] fluoro-2-deoxyD-glucose-positron emission tomography (FDG-PET). Summary Background Data: The 5-year overall survival after hepatic resection for colorectal cancer metastases without preoperative FDG-PET has been established in 19 studies (6070 patients). The median 5-year overall survival rate in these studies is 30% and has not improved over time. FDG-PET detects unsuspected tumor in 25% of patients considered to have resectable hepatic metastasis by conventional staging. Methods: From March 1995 to June 2002, all patients having hepatic resection for colorectal cancer metastases had preoperative FDG-PET. A prospective database was maintained. Results: One hundred patients (56 men, 44 women) were studied. Metastases were synchronous in 52, single in 63, unilateral in 78, and <5 cm in diameter in 60. Resections were major (>3 segments) in 75 and resection margins were greater than or equal to1 cm in 52. Median follow up was 31 months, with 12 actual greater than 5-year survivors. There was 1 postoperative death. The actuarial 5-year overall survival was 58% (95% confidence interval, 46-72%). Primary tumor grade was the only prognostic variable significantly correlated with overall survival. Conclusions: Screening by FDG-PET is associated with excellent postresection 5-year overall survival for patients undergoing resection of hepatic metastases from colorectal cancer. FDG-PET appears to define a new cohort of patients in whom tumor grade is a very important prognostic variable.
引用
收藏
页码:438 / 447
页数:10
相关论文
共 50 条
  • [41] Impact of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in recurrent colorectal cancer
    Metrard, G.
    Morel, O.
    Girault, S.
    Soulie, P.
    Guerin-Meyer, V.
    Lorimier, G.
    Jeanguillaume, C.
    Berthelot, C.
    Parot-Schinkel, E.
    Le Jeune, J-J
    Gamelin, E.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (09): : 547 - 552
  • [42] Prediction of response to chemotherapy using sequential F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with metastatic colorectal cancer
    Kim, J.
    Choi, S.
    Yi, H.
    Lim, J.
    Lee, M.
    Hyun, I.
    Kim, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Imaging in the Staging and Prognosis of Inflammatory Breast Cancer
    Alberini, Jean-Louis
    Lerebours, Florence
    Wartski, Myriam
    Fourme, Emmanuelle
    Le Stanc, Elise
    Gontier, E.
    Madar, O.
    Cherel, P.
    Pecking, A. P.
    CANCER, 2009, 115 (21) : 5038 - 5047
  • [44] F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma
    Majhail, NS
    Urbain, JL
    Albani, JM
    Kanvinde, MH
    Rice, TW
    Novick, AC
    Mekhail, TM
    Olencki, TE
    Elson, P
    Bukowski, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3995 - 4000
  • [45] Value of F-18 FDG Positron Emission Tomography in Evaluation of Patients with Esophageal Cancer
    Fragkaki, C.
    Kuker, R. A.
    Mathen, R.
    Ezuddin, S.
    Hickeson, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S163 - S163
  • [46] Fluoride-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in follow-up of endometrial cancer
    Bellon-Guardia, M. E.
    Rebollo-Aguirre, A. C.
    Cabello-Garcia, D.
    Ramos-Font, C.
    Gallego-Peinado, M.
    Moral-Ruiz, A.
    Rodriguez-Fernandez, A.
    Menjon, S.
    Olivencia, R.
    Llamas-Elvira, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S262 - S262
  • [47] Prospective evaluation of 18F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases
    Akhurst, Tim
    Gonen, Mithat
    Baser, Raymond E.
    Schwartz, Lawrence H.
    Tuorto, Scott
    Brody, Lynn A.
    Covey, Anne
    Brown, Karen T.
    Larson, Steven M.
    Fong, Yuman
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 539 - 554
  • [48] Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]fluorodeoxyglucose (FDG)
    Vollenweider, FX
    Leenders, KL
    Scharfetter, C
    Antonini, A
    Maguire, P
    Missimer, J
    Angst, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (01) : 9 - 24
  • [49] Role of fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging of patients with breast cancer candidated to surgery
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 62 - 62
  • [50] 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections
    Stroffolini, Giacomo
    Gaviraghi, Alberto
    Penna, Daniele
    Piccioni, Pavilio
    Venuti, Francesco
    Botto, Carlotta
    Trezzi, Michele
    Betti, Margherita
    Sestini, Stelvio
    Erba, Paola Anna
    Lupia, Tommaso
    Di Perri, Giovanni
    Aliberti, Stefano
    Calcagno, Andrea
    JOURNAL OF INFECTION, 2023, 87 (05) : 462 - 464